Cyclic amp analogues, individually and in pairs, to inhibit neoplastic cell growth

A pharmaceutical composition comprising a compound selected from the group consisting of phosphorothioate derivatives of cAMP analogues, wherein said cAMP analogues have been modified at either or both the N.sup.6 or C-8 positions of the adenine moiety, wherein said N.sup.6 - or C-6 substitution is selected from the group consisting of monobenzyl, monoethoxycarbonyl, monobenzoyl, monophenylcarbamoyl, monobutyryl, monophenyl, and diethyl or N-piperidino, and wherein said C-8 substituent is selected from the group consisting of halogen, methylthio, p-chlorophenylthio, .beta.-hydroxyethylamino and methylamino, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.

A method of inhibiting neoplastic cellular growth in a living mammal afflicted by said neoplastic cellular growth, which comprises administering a compound selected from the group consisting of phosphorothioate derivatives of cAMP analogues, wherein said cAMP analogues have been modified at either or both the N.sup.6 or C-8 positions of the adenine moiety, wherein said N.sup.6 - or C-6 substitution is selected from the group consisting of monobenzyl, monoethoxycarbonyl, monobenzoyl, monophenylcarbamoyl, monobutyryl, monophenyl, and diethyl or N-piperidino, and wherein said C-8 substituent is selected from the group consisting of halogen, methylthio, p-chlorophenylthio, .beta.-hydroxyethylamino and methylamino, and pharmaceutically acceptable salts thereof, in an amount sufficient to provide a serum concentration of about 0.1 to about 100 .mu.M in said mammal and inhibit said neoplastic cellular growth in said mammal.